[MAYBANK] QoQ TTM Result on 30-Jun-2018 [#2]

Announcement Date
30-Aug-2018
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2018
Quarter
30-Jun-2018 [#2]
Profit Trend
QoQ- 3.91%
YoY- 6.28%
View:
Show?
TTM Result
31/03/19 31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 CAGR
Revenue 48,780,993 47,319,853 46,871,578 46,404,324 45,817,576 45,580,310 45,040,284 5.46%
PBT 10,795,109 10,901,346 10,731,899 10,770,776 10,405,694 10,098,096 10,044,953 4.92%
Tax -2,463,844 -2,545,410 -2,575,679 -2,548,815 -2,454,436 -2,301,222 -2,049,090 13.08%
NP 8,331,265 8,355,936 8,156,220 8,221,961 7,951,258 7,796,874 7,995,863 2.77%
-
NP to SH 8,051,488 8,113,260 7,919,004 7,989,354 7,688,781 7,520,542 7,749,041 2.58%
-
Tax Rate 22.82% 23.35% 24.00% 23.66% 23.59% 22.79% 20.40% -
Total Cost 40,449,728 38,963,917 38,715,358 38,182,363 37,866,318 37,783,436 37,044,421 6.04%
-
Net Worth 78,200,815 75,330,108 72,734,615 71,853,940 72,802,528 72,420,516 69,459,874 8.23%
Dividend
31/03/19 31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 CAGR
Div 6,265,953 6,265,953 6,153,686 6,153,686 5,798,732 5,798,732 5,632,502 7.37%
Div Payout % 77.82% 77.23% 77.71% 77.02% 75.42% 77.11% 72.69% -
Equity
31/03/19 31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 CAGR
Net Worth 78,200,815 75,330,108 72,734,615 71,853,940 72,802,528 72,420,516 69,459,874 8.23%
NOSH 11,049,682 11,049,682 10,945,196 10,945,196 10,906,379 10,782,745 10,207,482 5.43%
Ratio Analysis
31/03/19 31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 CAGR
NP Margin 17.08% 17.66% 17.40% 17.72% 17.35% 17.11% 17.75% -
ROE 10.30% 10.77% 10.89% 11.12% 10.56% 10.38% 11.16% -
Per Share
31/03/19 31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 CAGR
RPS 441.47 428.25 429.05 424.94 422.67 426.03 441.25 0.03%
EPS 72.87 73.43 72.49 73.16 70.93 70.29 75.92 -2.69%
DPS 57.00 57.00 56.33 56.35 53.49 54.20 55.00 2.41%
NAPS 7.0772 6.8174 6.658 6.5799 6.716 6.769 6.8048 2.65%
Adjusted Per Share Value based on latest NOSH - 10,945,196
31/03/19 31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 CAGR
RPS 404.25 392.14 388.43 384.56 379.69 377.73 373.25 5.46%
EPS 66.72 67.24 65.63 66.21 63.72 62.32 64.22 2.58%
DPS 51.93 51.93 51.00 51.00 48.05 48.05 46.68 7.37%
NAPS 6.4806 6.2427 6.0276 5.9546 6.0332 6.0016 5.7562 8.23%
Price Multiplier on Financial Quarter End Date
31/03/19 31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 CAGR
Date 29/03/19 31/12/18 28/09/18 29/06/18 30/03/18 29/12/17 29/09/17 -
Price 9.27 9.50 9.79 9.00 10.60 9.80 9.53 -
P/RPS 2.10 2.22 2.28 2.12 2.51 2.30 2.16 -1.86%
P/EPS 12.72 12.94 13.51 12.30 14.94 13.94 12.55 0.90%
EY 7.86 7.73 7.40 8.13 6.69 7.17 7.97 -0.92%
DY 6.15 6.00 5.75 6.26 5.05 5.53 5.77 4.34%
P/NAPS 1.31 1.39 1.47 1.37 1.58 1.45 1.40 -4.33%
Price Multiplier on Announcement Date
31/03/19 31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 CAGR
Date 30/05/19 26/02/19 29/11/18 30/08/18 28/05/18 28/02/18 30/11/17 -
Price 9.01 9.55 9.45 9.96 10.00 10.46 9.25 -
P/RPS 2.04 2.23 2.20 2.34 2.37 2.46 2.10 -1.91%
P/EPS 12.37 13.01 13.04 13.61 14.10 14.88 12.18 1.03%
EY 8.09 7.69 7.67 7.35 7.09 6.72 8.21 -0.97%
DY 6.33 5.97 5.96 5.66 5.35 5.18 5.95 4.21%
P/NAPS 1.27 1.40 1.42 1.51 1.49 1.55 1.36 -4.46%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment